Synerzys Novaceuticals Private Limited
Synerzys Novaceuticals Private Limited is a Private Indian company incorporated in 2015 and based in Telangana, India. Synerzys Novaceuticals Private Limited operates in Pharmaceuticals & Chemicals (NIC 24100) with authorized capital of —. RegisterKaro's Compliance Health Score for the company is 30/100 (grade F), reflecting a weak compliance posture.
Quick facts
Directors
LockedDirectors, DINs & appointment history for Synerzys Novaceuticals Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
MCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | 0d | filed |
| MGT-7 | FY2024-25 | 26 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | 0d | filed |
| MGT-7 | FY2023-24 | 23 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 27 Nov 2022 | 29 Nov 2022 | 0d | filed |
Full MCA filing history for Synerzys Novaceuticals Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 153868624 | HDFC Bank Ltd(Bank) | ₹6.76 Cr | 12 Mar 2023 | Satisfied |
| 597978019 | Axis Bank Ltd(Bank) | ₹3.88 Cr | 19 Sep 2023 | Satisfied |
| 985489113 | HDFC Bank Ltd(Bank) | ₹19.18 Cr | 27 Jan 2020 | Satisfied |
| 120220124 | Axis Bank Ltd(Bank) | ₹10.49 Cr | 04 Jul 2023 | Satisfied |
| 380065571 | HDFC Bank Ltd(Bank) | ₹17.78 Cr | 04 Jul 2019 | Satisfied |
| 725536543 | HDFC Bank Ltd(Bank) | ₹18.44 Cr | 27 Jan 2023 | Satisfied |
Charge IDs, lenders & amounts for Synerzys Novaceuticals Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
Locked| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| FY2024-25 | ₹18.57 Cr | ₹79.17 L | ₹20.05 Cr | ₹29.19 Cr | 330 |
| FY2023-24 | ₹16.28 Cr | ₹96.91 L | ₹13.24 Cr | ₹20.27 Cr | 278 |
| FY2022-23 | ₹14.74 Cr | ₹1.15 Cr | ₹11.92 Cr | ₹19.30 Cr | 181 |
| FY2021-22 | ₹15.27 Cr | ₹67.21 L | ₹14.03 Cr | ₹23.18 Cr | 17 |
Audited financials & ratios for Synerzys Novaceuticals Private Limited.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Detailed Financials
Locked| Line item | FY2024-25 | FY2023-24 | FY2022-23 | FY2021-22 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ₹18.57 Cr | ₹16.28 Cr | ₹14.74 Cr | ₹15.27 Cr |
| Other income | ₹32.52 L | ₹31.82 L | ₹25.44 L | ₹59.05 L |
| Total income | ₹18.89 Cr | ₹16.59 Cr | ₹14.99 Cr | ₹15.86 Cr |
| Total expenses | ₹17.88 Cr | ₹15.35 Cr | ₹13.52 Cr | ₹15.00 Cr |
| Profit before tax | ₹1.03 Cr | ₹1.26 Cr | ₹1.49 Cr | ₹87.37 L |
| Profit / (Loss) after tax | ₹79.17 L | ₹96.91 L | ₹1.15 Cr | ₹67.21 L |
| Balance sheet | ||||
| Equity / Net worth | ₹20.05 Cr | ₹13.24 Cr | ₹11.92 Cr | ₹14.03 Cr |
| Borrowings | ₹3.34 Cr | ₹3.86 Cr | ₹2.88 Cr | ₹2.14 Cr |
| Current liabilities | ₹3.40 Cr | ₹3.98 Cr | ₹2.33 Cr | ₹4.24 Cr |
| Total liabilities | ₹9.14 Cr | ₹7.03 Cr | ₹7.38 Cr | ₹9.15 Cr |
| Current assets | ₹15.59 Cr | ₹10.07 Cr | ₹11.07 Cr | ₹12.63 Cr |
| Cash & equivalents | ₹3.71 Cr | ₹2.58 Cr | ₹3.42 Cr | ₹2.08 Cr |
| Total assets | ₹29.19 Cr | ₹20.27 Cr | ₹19.30 Cr | ₹23.18 Cr |
| Employees | 330 | 278 | 181 | 17 |
Audited financials & ratios for Synerzys Novaceuticals Private Limited.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Compounded Annual Growth Rate
Locked| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue | ₹18.57 Cr | +7.6% | +14.1% | -0.0% |
| Profit after Tax | ₹79.17 L | +1.1% | +2.4% | +19.3% |
| Net Worth | ₹20.05 Cr | +2.6% | +12.7% | +4.0% |
| Employees | 330 | +6.3% | +7.2% | +21.6% |
Audited financials & ratios for Synerzys Novaceuticals Private Limited.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Financial Ratios
Locked| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| FY2024-25 | ₹18.57 Cr | ₹79.17 L | +4.26% | +19.22% | +3.95% | +2.71% | 0.17 | ₹5.63 L |
| FY2023-24 | ₹16.28 Cr | ₹96.91 L | +5.95% | +38.31% | +7.32% | +4.78% | 0.29 | ₹5.85 L |
| FY2022-23 | ₹14.74 Cr | ₹1.15 Cr | +7.78% | +17.85% | +9.62% | +5.94% | 0.24 | ₹8.14 L |
| FY2021-22 | ₹15.27 Cr | ₹67.21 L | +4.40% | +28.62% | +4.79% | +2.90% | 0.15 | ₹89.81 L |
Audited financials & ratios for Synerzys Novaceuticals Private Limited.
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 4 | 1,88,74,685 | 59.93% |
| Institutional Investors | 1 | 49,62,410 | 15.76% |
| Public & Others | 36 | 76,58,886 | 24.32% |
Promoter, institutional & public holding for Synerzys Novaceuticals Private Limited.
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
338 peersExternal data sources
7 plannedGSTIN Registrations
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
Applied, registered, opposed. Class numbers + status.
Patents
Applications and grants. Inventor names + filing dates.
Legal Cases
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.